Financial Data and Key Metrics Changes - The net loss for the year ended December 31, 2025, was approximately $34.5 million or $0.74 per basic and diluted share, compared to a net loss of $37.6 million or $1.03 per basic and diluted share for the year ended December 31, 2024, indicating an improvement in financial performance [15] - Research and development expenses for the year ended December 31, 2025, were $19 million, down from $22.6 million in 2024, primarily due to decreases in manufacturing and personnel costs [15] - General and administrative expenses decreased to $12.5 million in 2025 from $13.8 million in 2024, reflecting a reduction in personnel costs [16] Business Line Data and Key Metrics Changes - The company reported encouraging early results from the PDS-01ADC trial, showing a median progression-free survival (PFS) of 9.6 months and a 40% median decline in prostate-specific antigen (PSA) levels in patients with metastatic castration-resistant prostate cancer [5][6] - The VERSATILE-002 trial demonstrated a median overall survival of 39.3 months for patients with HPV-16 positive head and neck cancer, marking a significant clinical achievement [9] Market Data and Key Metrics Changes - The company highlighted the growing unmet need for treatments in HPV-16 positive cancers, which are rapidly increasing in the U.S. and EU due to low vaccination rates [12] - The amendment to the VERSATILE-003 trial protocol aims to accelerate the availability of PDS0101 to the growing population of HPV-16 positive patients [11] Company Strategy and Development Direction - The company is focused on advancing PDS0101 as a promising treatment option for HPV-16 positive head and neck cancer, with a strategic amendment to the VERSATILE-003 trial to include PFS as a primary endpoint [4][10] - The company has strengthened its intellectual property portfolio with new patents granted in the U.S. and Japan, extending market protection into the 2040s [6] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the potential of PDS0101 to provide a well-tolerated treatment option without chemotherapy for HPV-16 positive patients, who currently lack effective therapies [14] - The company anticipates meaningful opportunities ahead as it continues to execute its priorities in 2026, particularly with the early data from the PDS-01ADC program [38] Other Important Information - The company emphasized the convenience of PDS0101 as a subcutaneous injection requiring only five doses, compared to over twenty doses for most therapeutic approaches [12] Q&A Session Summary Question: What will the revised enrollment target look like for the amended protocol? - The trial duration has been shortened to about a year for final results, with the interim analysis for PFS expected in approximately a year and a half [20] Question: How should R&D expenses be expected for 2026 with the smaller trial design? - While specific financial guidance was not provided, R&D costs are expected to increase once the trial is reinitiated, commensurate with site openings and patient enrollment [23] Question: How will patients already enrolled prior to the VERSATILE-003 pause be handled? - Patients who started on the trial will continue their treatment as indicated by the protocol, and they will be included in a special subset of the data for safety [27] Question: What is the expected enrollment pace based on last year's execution? - The enrollment pace is expected to be robust due to positive responses from sites and less competition compared to when the trial first began [29] Question: Can you share the powering assumptions for the interim PFS and the new sample size for the phase III? - The sample size has not been made public yet, but the PFS is powered to detect statistically significant changes, with two interim analyses planned [34]

Financial Data and Key Metrics Changes - Revenue and other income amounted to EUR 9 million, including EUR 2.8 million from licensing and collaboration agreements and EUR 6.2 million in governmental funding for research expenditures [55] - Operating expenses were EUR 63 million, with R&D expenses decreasing by 16% year-over-year to EUR 43.6 million, reflecting study maturity and reduced indirect R&D expenses [56] - Cash position at the end of 2025 was EUR 44.8 million, providing funding visibility until the end of the third quarter of 2026 [57] Business Line Data and Key Metrics Changes - Focus on three priority programs: lacutamab, IPH4502, and monalizumab, with significant progress reported in each [6][11] - Lacutamab received FDA clearance for the TELLOMAK 3 phase III trial, expected to initiate in the second half of 2026 [8][18] - IPH4502 is advancing rapidly with early signs of antitumor activity in heavily pretreated patients, particularly in urothelial cancer [9][40] Market Data and Key Metrics Changes - Estimated 300 incident patients per year in Sézary syndrome in the U.S., with a prevalence of around 1,000 patients, primarily treated in specialized academic centers [22] - Mycosis fungoides represents a larger opportunity with approximately 3,000 incident patients per year and a prevalence of around 12,000 patients in the U.S. [25] - Mogamulizumab generated approximately $300 million in annual sales in 2025, projected to reach $350 million in 2026 [25] Company Strategy and Development Direction - Company aims to deliver high-value differentiated therapies for patients with significant unmet medical needs, focusing on late-stage development of its pipeline [4][5] - Strategic focus on three high-value clinical assets allows for concentrated resource allocation to generate clinical impact and long-term value [6] - Plans to leverage internal expertise and platform capabilities to advance the next generation of antibody-drug conjugates (ADCs) [6] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the potential of IPH4502 to address significant unmet needs in the post-PADCEV setting and expand into other tumor types [60] - The company is negotiating non-dilutive financing options to support the initiation of the TELLOMAK 3 study for lacutamab [61] - Upcoming data readouts for monalizumab and IPH4502 are expected to create inflection points for the company [110] Other Important Information - The partnership with AstraZeneca for monalizumab includes potential milestones of up to $1.275 billion, with $450 million already received [52] - The MATISSE phase II trial for IPH5201 is ongoing, with results from an interim analysis expected to be presented at the AACR Annual Meeting [51] Q&A Session Summary Question: Updates on IPH4502 program and competitive positioning - Management highlighted strong interest in IPH4502 and its differentiation as a topo 1 ADC, focusing on the post-PADCEV setting [66] Question: MATISSE interim data presentation at AACR - The interim analysis will provide insights into the trial's efficacy and the potential path forward for lung cancer development [70] Question: Collaboration revenue from monalizumab program - Management clarified that revenue from the old agreement has dropped as the project is now fully under AstraZeneca's control [72] Question: Updates on lacutamab partnership discussions - Management is evaluating options for financing and partnership structures to maximize shareholder value [90] Question: Sales infrastructure for lacutamab - If pursued independently, a small sales team of around 20 people would be needed, focusing on specialized academic centers [105]

Financial Data and Key Metrics Changes - Revenue and other income amounted to EUR 9 million, including EUR 2.8 million from licensing and collaboration agreements and EUR 6.2 million in governmental funding for research expenditures [33] - Operating expenses were EUR 63 million, with R&D expenses decreasing by 16% year-over-year to EUR 43.6 million, reflecting study maturity and reduced indirect R&D expenses [33] - Cash position at the end of 2025 was EUR 44.8 million, providing funding visibility until the end of the third quarter of 2026 [33] Business Line Data and Key Metrics Changes - The company is prioritizing three high-value clinical assets: IPH4502, lacutamab, and monalizumab, focusing resources on these areas to generate clinical impact and long-term value [5][6] - Lacutamab has received FDA clearance to proceed with the TELLOMAK 3 phase III trial, expected to initiate in the second half of 2026 [7][10] - IPH4502 is progressing rapidly with early signs of antitumor activity in heavily pretreated patients, particularly in urothelial cancer [7][8] Market Data and Key Metrics Changes - The market for lacutamab in CTCL is concentrated, with approximately 300 incident patients per year in Sézary syndrome and around 1,000 patients in total, primarily treated in specialized academic centers [14][15] - Mycosis fungoides represents a larger opportunity with approximately 3,000 incident patients per year and a prevalence of around 12,000 patients in the U.S. [15] - Mogamulizumab generated approximately $300 million in annual sales in 2025, projected to reach $350 million in 2026, highlighting the market potential for lacutamab [15] Company Strategy and Development Direction - The company aims to advance its pipeline of differentiated therapies for significant unmet medical needs, focusing on late-stage development and key clinical and regulatory milestones [4][5] - A streamlined organization supports efficient decision-making and disciplined capital allocation, with a redundancy plan expected to be completed by the end of April [5] - The strategic focus on high-value clinical assets allows the company to concentrate resources effectively [5] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the progress of IPH4502 and its potential to address unmet needs in the post-PADCEV setting, with a focus on expanding into earlier lines of therapy [36] - The company is negotiating non-dilutive financing options to support the initiation of the TELLOMAK 3 study for lacutamab [36] - The upcoming data readouts for monalizumab and IPH4502 are expected to create significant inflection points for the company [36][37] Other Important Information - The partnership with AstraZeneca for monalizumab and IPH5201 includes potential milestone payments of up to $1.275 billion and $885 million, respectively [31][32] - The MATISSE phase II trial for IPH5201 is ongoing, with results from an interim analysis expected to be presented at the AACR Annual Meeting [30][44] Q&A Session Summary Question: Can you provide specifics regarding the IPH4502 program and its competitive positioning? - Management highlighted strong interest in IPH4502 and its differentiation as a Topo 1 ADC, focusing on the post-PADCEV setting [40][41] Question: What can be expected from the MATISSE interim data presentation at AACR? - The interim analysis will provide insights into the trial's efficacy and the potential path forward for development in lung cancer [44] Question: What is the status of collaboration revenue from the monalizumab program? - Revenue from the collaboration has dropped as the project is now fully under AstraZeneca's control, with future development dependent on upcoming results [46] Question: How does CD39 fit in relation to CD73 in the context of the MATISSE trial? - CD39 is upstream in the adenosine pathway, and blocking it can enhance immune stimulation, making it a valuable target in combination with chemotherapy [55][56] Question: What sales infrastructure is the company considering for lacutamab? - The company is evaluating whether to build its own sales team or partner with a BD partner, estimating a small commercial infrastructure would suffice for the CTCL market [72]

Financial Data and Key Metrics Changes - Revenue and other income for 2025 amounted to EUR 9 million, including EUR 2.8 million from licensing and collaboration agreements and EUR 6.2 million in governmental funding for research expenditures [33] - Operating expenses were EUR 63 million, with R&D expenses at EUR 43.6 million, a decrease of 16% year-over-year, reflecting study maturity and reduced indirect R&D expenses [33] - Cash position at the end of 2025 was EUR 44.8 million, providing funding visibility until the end of Q3 2026 [33] Business Line Data and Key Metrics Changes - The company is focusing on three high-value clinical assets: IPH4502, lacutamab, and monalizumab, with significant progress reported in their development [5][6] - IPH4502 is showing preliminary antitumor activity in heavily pretreated patients, particularly in urothelial cancer [7][23] - Lacutamab has received FDA clearance for the TELLOMAK 3 phase III trial, expected to initiate in the second half of 2026 [9][10] Market Data and Key Metrics Changes - In the U.S., there are approximately 300 incident patients per year in Sézary syndrome, with a prevalence of around 1,000 patients, primarily treated in specialized academic centers [14][15] - Mycosis fungoides represents a larger opportunity with approximately 3,000 incident patients per year and a prevalence of around 12,000 patients in the U.S. [16] Company Strategy and Development Direction - The company aims to deliver high-value differentiated therapies for significant unmet medical needs, focusing on late-stage development of its pipeline [5][6] - A strategic focus on IPH4502, lacutamab, and monalizumab allows for concentrated resource allocation to generate clinical impact and long-term value [6] - The company is exploring potential pharma partnerships and royalty-based structures to support late-stage development while preserving shareholder value [7] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the progress of their clinical programs and the potential for multiple catalysts in the near and medium term [8][36] - The company is negotiating non-dilutive financing options to support the initiation of the TELLOMAK 3 study for lacutamab [36] Other Important Information - The partnership with AstraZeneca for monalizumab and IPH5201 includes significant milestone payments, with potential royalties on sales [31][32] - The company has streamlined its organization to ensure efficient decision-making and disciplined capital allocation [6] Q&A Session Summary Question: Can you provide specifics regarding the IPH4502 program and its competitive positioning? - Management highlighted strong interest in IPH4502 and its differentiation as a Topo 1 ADC, focusing on the post-PADCEV setting [39][40] Question: What can be expected from the MATISSE interim data presentation at AACR? - The interim analysis will provide insights into the trial's efficacy and the potential path forward for development in lung cancer [42][44] Question: How is the collaboration revenue from the monalizumab program expected to evolve? - Future development will depend on upcoming results from the PACIFIC-9 trial, with current revenue reflecting the transition to AstraZeneca's control [45] Question: What updates can be shared regarding lacutamab's partnership discussions? - The company is evaluating options for financing and partnerships to bring lacutamab to market efficiently [58][60] Question: What kind of sales infrastructure is being considered for lacutamab? - If pursued independently, a small sales team of around 20 people would be sufficient due to the concentrated treatment landscape [70][71]

Core Insights - CStone Pharmaceuticals has made significant advancements in its global commercialization and innovation pipeline, particularly with sugemalimab and CS2009, positioning itself for future growth and market expansion [1][6][9] R&D Pipeline - The company is advancing its Pipeline 2.0, with CS2009 (PD-1/VEGF/CTLA-4 trispecific antibody) showing promising clinical efficacy, particularly in lung cancer, with an overall response rate (ORR) of 90% in first-line NSCLC patients [3][13] - Three next-generation antibody-drug conjugates (ADCs) are set to present preclinical findings at AACR 2026, with IND submissions planned for the same year [2][19] - CS5001 (ROR1 ADC) is in a global Phase Ib trial, demonstrating a complete response (CR) rate exceeding 90% when combined with R-CHOP for DLBCL [15][16] Commercialization Efforts - Sugemalimab has expanded its global footprint, securing two new strategic partnerships and regulatory approvals in over 60 countries, including the EU and UK for Stage III NSCLC [1][16][17] - GAVRETO® (pralsetinib) has received approval for local manufacturing in China and was included in the National Reimbursement Drug List (NRDL), which is expected to drive significant sales growth [4][17] - AYVAKIT® (avapritinib) has commenced domestic supply in China and successfully renewed its NRDL inclusion, enhancing its market position [4][18] Financial Performance - For the year ended December 31, 2025, CStone reported revenue of RMB269.6 million, with a notable decrease in pralsetinib sales due to price adjustments ahead of NRDL negotiations [5][22] - The company maintains a solid financial position with cash and cash equivalents totaling RMB918.7 million as of December 31, 2025, allowing for continued investment in R&D [8][22] Future Outlook - CStone aims to initiate multiple global Phase III trials for CS2009 by the end of 2026, targeting various solid tumor indications [14][20] - The company is committed to maximizing the commercial value of its established products while advancing its innovative pipeline, focusing on long-term value creation for shareholders [9][20]

Core Insights - Purple Biotech has announced a collaboration with Converge Bio to enhance its tri-specific antibody platform using generative AI for oncology applications [1][3] - The collaboration aims to accelerate drug discovery timelines and improve the quality of therapeutic candidates targeting solid tumors [1][4] Company Overview - Purple Biotech is a clinical-stage company focused on developing next-generation immunotherapy platforms that maximize anti-cancer potency while minimizing toxicity [9] - The company's lead program, CAPTN-3, involves masked tri-specific antibodies that engage both T cells and NK cells, enhancing therapeutic efficacy [8][9] Collaboration Details - The partnership will leverage Converge Bio's AI platform, which integrates large-scale biological data with predictive modeling to optimize antibody candidates [3][5] - This collaboration is expected to expand Purple Biotech's pipeline with high-quality candidates while reducing development timelines [4][6] Technology and Innovation - The CAPTN-3 platform utilizes proprietary capping technology to confine immune activation to the tumor microenvironment, significantly improving the therapeutic window compared to traditional T-cell engagers [8][9] - The collaboration aims to develop novel T cell engagers that combine optimal functional properties with favorable physicochemical characteristics [3][4] Strategic Goals - The integration of AI into Purple Biotech's development strategy positions the company at the forefront of innovation in multi-specific antibody therapies [3][5] - The collaboration is seen as a strategic expansion to address additional high-value oncology targets and resistance mechanisms [6]

Core Insights - OSE Immunotherapeutics is actively participating in investor conferences to engage with wealth managers, financial advisors, and individual investors, showcasing its commitment to transparency and investor relations [1][2]. Company Overview - OSE Immunotherapeutics is a clinical-stage biotech company focused on developing first-in-class therapies in immuno-oncology and immuno-inflammation, addressing unmet patient needs [3]. - The company collaborates with leading academic institutions and biopharmaceutical companies to develop transformative medicines for serious diseases [3]. - OSE Immunotherapeutics is headquartered between Nantes and Paris and is listed on Euronext [3]. Upcoming Events - The company will present at the Mardi de la Bourse event in Lyon, France, on April 7, 2026, where the CEO and CFO will engage in a Q&A session [1]. - Additionally, OSE Immunotherapeutics will host investor meetings at the 14th Degroof Petercam Healthcare Conference on May 6, 2026, in a virtual format [2].

Core Viewpoint - Phio Pharmaceuticals Corp. is advancing its lead product candidate, PH-762, which utilizes INTASYL® gene silencing technology for the treatment of skin cancers, with a presentation scheduled at the American Academy of Dermatology's Late-Breaking Research Session on March 28, 2026 [1][2]. Company Highlights - PH-762 is being evaluated as an intratumoral therapy for cutaneous squamous cell carcinoma (cSCC), melanoma, and Merkel cell carcinoma [4]. - In the Phase 1b trial, 22 patients completed treatment across five dose-escalation cohorts, reporting no dose-limiting toxicities or serious adverse events [4]. - The pathological response rate in cSCC across all dosing cohorts is approximately 65%, with an 85% response rate in the highest-dose cohort [4]. Clinical Development - The upcoming presentation will focus on the results of the Phase 1b clinical study (NCT 06014086) assessing the safety and tolerability of PH-762 [2][3]. - Preliminary clinical evidence suggests that intratumoral PH-762 may provide substantial clinical benefits, including notable pathologic response and modest mean reductions in tumor burden [3]. Future Plans - The company plans to engage with the FDA regarding the next stage of clinical development in the second quarter of 2026 [5]. - Phio has reported cash and cash equivalents that are projected to sustain operations into the first half of 2027 [5].

Core Insights - Tonix Pharmaceuticals Holding Corp. announced presentations on its preclinical immuno-oncology portfolio at the AACR Annual Meeting 2026, scheduled for April 17–22, 2026, in San Diego, California [1] Oral Presentation Details - The oral presentation titled "TFF2 deficiency amplifies IL-1β-driven inflammation and promotes aging-associated gastric tumor progression" will take place on April 21, 2026, from 2:30–4:30 p.m. PT [2] - Presenters include Shuang Li, MD, PhD, and Timothy C. Wang, MD, with Tonix co-authors Seth Lederman, MD, and Bruce L. Daugherty, PhD, MBA [2] Poster Presentation Details - The first poster presentation titled "In vitro characterization of fully human antagonistic anti-BTLA monoclonal antibodies" is scheduled for April 21, 2026, from 2:00-5:00 p.m. PT [3] - The second poster presentation titled "Pharmacokinetics of TNX-1700 in non-human primates and human FcRn/serum albumin transgenic mice" will occur on April 22, 2026, from 9:00 a.m.–12:00 p.m. PT [3] - Both presentations will be led by Bruce Daugherty, PhD, MBA [3] About TNX-1700 - TNX-1700 is a fusion protein of TFF2 and albumin, currently in preclinical development for treating gastric and colorectal cancer in combination with PD-1 blockade [4] - The drug is in the pre-Investigational New Drug (IND) stages of development and was in-licensed from Columbia University [4] Company Overview - Tonix Pharmaceuticals is a fully-integrated, commercial-stage biotechnology company focused on CNS and immunology treatments for high unmet medical needs [5] - The company’s marketed products include TONMYA for fibromyalgia, Zembrace® Symtouch® for acute migraines, and Tosymra® [5] - Tonix is also investigating TONMYA in Phase 2 clinical trials for major depressive disorder and acute stress disorder, and has a pipeline including TNX-2900 for Prader-Willi syndrome and monoclonal antibodies for Lyme disease prophylaxis and kidney transplant rejection [5]

Core Insights - ImmunityBio (IBRX) is transitioning into a commercial-stage immunotherapy developer, with its future closely linked to Anktiva, its primary asset driving revenue and regulatory milestones [2][3] Business Overview - ImmunityBio focuses on immunotherapies that activate both innate and adaptive immune systems, with Anktiva as the lead product and key revenue driver [3][4] - Anktiva is an interleukin-15 receptor superagonist antibody-cytokine fusion protein aimed at stimulating natural killer cells and T cells, positioning it as a versatile immuno-oncology platform [4] Revenue Growth - In 2025, ImmunityBio reported total revenue of $113.3 million, a significant increase from $14.7 million in 2024, primarily driven by Anktiva sales [6][11] - The revenue growth is attributed to the launch timeline, with initial shipments starting in May 2024 following FDA approval in April 2024 [7] Adoption and Market Trends - In Q4 2025, net product sales reached $38.3 million, reflecting a 20% quarter-over-quarter growth, indicating increasing demand as the company enters 2026 [9][11] - Repeat prescribing behavior among physicians is a positive adoption indicator, suggesting sustained ordering patterns as providers gain experience with Anktiva [10] International Expansion - ImmunityBio is expanding its international footprint, with conditional marketing authorization granted in Europe and Saudi Arabia for Anktiva, enhancing commercial opportunities [13][14] - A commercial team led by Accord Healthcare will target 31 European countries, with Germany prioritized for early launches in 2026 [15] Label Expansion Efforts - Label expansion is a critical value driver, with Anktiva showing a 71% complete response rate in a phase II/III study for BCG-unresponsive CIS [16] - The company is also pursuing earlier-line opportunities and plans to file for U.S. approval by the end of 2026 based on interim analysis results [17] Regulatory Developments - A supplemental biologics license application for Anktiva combined with BCG in BCG-unresponsive NMIBC with papillary disease is set for resubmission on March 9 [18]